28
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Determination of a Novel Antiangiogenic Agent KR‐31831 in Rat Plasma by Liquid Chromatography‐Tandem Mass Spectrometry

, , , , , , , & show all
Pages 283-292 | Received 01 Aug 2003, Accepted 01 Sep 2003, Published online: 16 Aug 2010
 

ABSTRACT

A liquid chromatography‐tandem mass spectrometric (LC/MS/MS) method was developed for the determination of a new anti‐angiogenic drug KR‐31831 in rat plasma. KR‐31831 and internal standard, KR‐31543 were extracted from rat plasma with dichloromethane at basic pH. A reverse‐phase LC separation was performed on Luna C8 column with the mixture of acetonitrile‐ammonium formate (10 mM, pH 4.5) (67:33, v/v) as mobile phase. The detection of analytes was performed using an electrospray ionization tandem mass spectrometry in the multiple‐reaction‐monitoring mode. The standard curve was linear (r = 0.999) over the concentration range of 1.0–500 ng/mL. The coefficient of variation of intra‐ and inter‐assay ranged from 0.8–3.9% and 1.4–3.9%, respectively. The recoveries of KR‐31831 ranged from 80.9% to 86.7%, with that of KR‐31543 (internal standard) being 99.2 ± 2.7%. The lower limits of quantification for KR‐31831 was 1.0 ng/mL using 100 µL plasma sample. This method was applied to the pharmacokinetic study of KR‐31831 in rats.

ACKNOWLEDGMENT

This work was partially supported by the Project from the Center for Biological Modulators (CBM‐02‐B‐8), Ministry of Science and Technology, Republic of Korea.

Notes

Note: —, Not assayed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.